Drug intelligence / Profile preview

Bupi Xiaoji

Development stage: Preclinical
Lead developer: Xijing Hospital
Administration: Oral

Overview

Bupi Xiaoji is a Traditional Chinese Medicine (TCM) oral liquid formulation developed by The First Affiliated Hospital of Air Force Military Medical University (Xijing Hospital). It is primarily indicated for the treatment of pediatric mesenteric lymphadenitis, a condition characterized by inflammation of the lymph nodes within the mesentery. The formulation is designed based on TCM principles to tonify the spleen (Bupi) and eliminate accumulation (Xiaoji), addressing symptoms such as abdominal pain and digestive dysfunction. It is currently being evaluated in clinical trials to assess its efficacy and safety when combined with basic treatments for children.

Other names: Bupi Xiaoji oral liquidBupi Xiaoji Koufuye

Beyond the preview

Go deeper on Bupi Xiaoji.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bupi Xiaoji.

Explore the full profile